639090-54-3

Basic information

• Product Name: N-(4-sulfanylphenyl)cyclopropanecarboxamide
• Synonyms: N-(4-sulfanylphenyl)cyclopropanecarboxamide;Cyclopropanecarboxylic acid N-(4-sulfanylphenyl)amide;N-(4-mercaptophenyl)cyclopropanecarboxamide
• CAS NO: 639090-54-3
• Molecular Formula: C₁₀H₁₁NOS
• Molecular Weight: 193.27
• Mol File: 639090-54-3.mol

Chemical Properties

• Boiling Point: 408.6°C at 760 mmHg
• Flash Point: 200.9°C
• Appearance: /
• Density: 1.338
• Vapor Pressure: 6.93E-07mmHg at 25°C
• Refractive Index: 1.698
• Storage Temp.: 2-8°C
• PKA: 6.90±0.10(Predicted)
• CAS DataBase Reference: N-(4-sulfanylphenyl)cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-sulfanylphenyl)cyclopropanecarboxamide(639090-54-3)
• EPA Substance Registry System: N-(4-sulfanylphenyl)cyclopropanecarboxamide(639090-54-3)

Safety Data

• Hazardous Substances Data: 639090-54-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
N-(4-Sulfanylphenyl)cyclopropanecarboxamide is used as a research compound for the development of new pharmaceutical products. Its unique chemical structure and properties make it a valuable candidate for exploring potential therapeutic applications and drug interactions.
Used in Chemical Industry Research and Development:
In the chemical industry, N-(4-Sulfanylphenyl)cyclopropanecarboxamide is used as a research compound to investigate its potential applications in various chemical processes and reactions. Its high density and solubility in various solvents make it an interesting subject for further exploration and development.

InChI:InChI=1/C10H11NOS/c12-10(7-1-2-7)11-8-3-5-9(13)6-4-8/h3-7,13H,1-2H2,(H,11,12)

Upstream product

• 4023-34-1 cyclopropanecarboxylic acid chloride 
• 1193-02-8 4-aminotiophenol 
• 1759-53-1 cyclopropanecarboxylic acid 

Downstream Products

• 639090-53-2 N-{4-[(4,6-dichloropyrimidin-2-yl)sulfanyl]phenyl}cyclopropane carboxamide 
• 883734-21-2 N-(4-(8-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrazin-6-ylthio)phenyl)cyclopropane carboxamide 
• 883734-23-4 N-(4-(5-(5-Methyl-1H-pyrazol-3-ylamino)imidazo[1,2-a]pyrimidin-7-ylthio)phenyl)-cyclopropane carboxamide 
• 883734-14-3 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide 
• 883737-15-3 N-(4-(2-ethyl-5-(5-methyl-1H-pyrazol-3-ylamino)imidazo[1,2-c]pyrimidin-7-ylthio)phenyl)cyclopropanecarboxamide 
• 883734-19-8 N-(4-(5-(5-methyl-1H-pyrazol-3-ylamino)-[1,2,4]triazolo[1,5-f]pyrimidin-7-ylthio)phenyl)cyclopropane carboxamide 
• 1088937-37-4 (S)-N-(4-(4-(3-fluoropyrrolidin-1-yl)-6-(3-methyl-1H-pyrazol-5-ylamino)pyridin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1088937-35-2 (S)-N-(4-(4-(3-fluoropyrrolidin-1-yl)-6-(5-methylthiazol-2-ylamino)pyridin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 639090-55-4 N-[4-({4-chloro-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidin-2-yl}sulfanyl)phenyl]cyclopropane carboxamide 
• 1170188-57-4 N-(4-(4-(2-aminoethylamino)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1450754-47-8 N-(4-(4-(2-(3-(but-3-ynyl)-3H-diazirin-3-yl)ethylamino)-6-(3-methyl-1H-pyrazol-5-ylamino)pyrimidin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1258424-92-8 N-(4-(4-(5-methyl-1H-pyrazol-3-ylamino)-6-(piperazin-1-yl)-1,3,5-triazin-2-ylthio)phenyl)cyclopropanecarboxamide 
• 1258223-00-5 N-(4-((4,6-dichloro-1,3,5-triazin-2-yl)thio)phenyl)cyclopropanecarboxamide 
• 639089-54-6 tozasertib 

Relevant articles and documents

Tozasertib Analogues as Inhibitors of Necroptotic Cell Death

Receptor interacting protein kinase 1 (RIPK1) plays a crucial role in tumor necrosis factor (TNF)-induced necroptosis, suggesting that this pathway might be druggable. Most inhibitors of RIPK1 are classified as either type II or type III kinase inhibitors. This opened up some interesting perspectives for the discovery of novel inhibitors that target the active site of RIPK1. Tozasertib, a type I pan-aurora kinase (AurK) inhibitor, was found to show a very high affinity for RIPK1. Because tozasertib presents the typical structural elements of a type I kinase inhibitor, the development of structural analogues of tozasertib is a good starting point for identifying novel type I RIPK1 inhibitors. In this paper, we identified interesting inhibitors of mTNF-induced necroptosis with no significant effect on AurK A and B, resulting in no nuclear abnormalities as is the case for tozasertib. Compounds 71 and 72 outperformed tozasertib in an in vivo TNF-induced systemic inflammatory response syndrome (SIRS) mouse model.

As inhibitors of Aurora kinases substituted pyrimidine derivatives

The present invention relates to a substituted and aurora kinase-inhibiting pyrimidine derivative as represented by formula (I) or (Ia), tautomer, hydrate, solvate, ester or pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the compounds as active ingredients, as well as uses of the compounds and the pharmaceutical composition thereof in the preparation of drugs for protecting against, treating, curing or alleviating proliferative diseases of a patient.

COMPOUNDS AND METHODS OF USE THEREOF FOR TREATING NEURODEGENERATIVE DISORDERS

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed.

Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling

Less is more: A minimalist "clickable" photo-crosslinker (see scheme) was incorporated with numerous small-molecule kinase inhibitors. The resulting probes were used for both in vitro (cell lysates) and in situ (live cells) proteome profiling, for large-scale identification of their potential cellular kinase targets and shows improved outcomes over previous probes. Copyright

DRUG DISCOVERY METHODS

The present invention relates to drug discovery methods, particularly methods for assaying compounds for activity as Aurora kinase inhibitors. This invention also relates to a pharmacophore describing compounds that are able to promote a conformational ch

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.

TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS

The invention provides Triazine derivatives and further provides methods of using these compounds to modulate protein kinases and for treating diseases and conditions mediated by protein kinases.

AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of Aurora protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment

AURORA INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to Aurora inhibitors and their use in the treatment of cell proliferative diseases such as cancer. The said derivatives may further act as HDAC inhibitors.

KINASE INHIBITORS

Disclosed are protein kinase inhibitors of Formula Ia and Ib, compositions comprising such inhibitors, and methods of use, thereof. More particularly, these compounds and compositions are inhibitors of Aurora-A (Aurora-2) and Aurora-B (Aurora-1) protein k